Charlie Bolten was recruited to BioGenerator in July of 2009. At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology project focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor. Prior to his work in immunology, Charlie led a Pfizer project targeting a mitochondrial protein involved in diabetes, and worked on biomarkers and pharmacology for several nuclear receptor projects.
Before Pfizer, Charlie worked on pharma project teams in various therapeutic areas at Pharmacia and Searle, as well as in technology and screening groups. Charlie began his career in agricultural research at Monsanto, mainly in the area of genomics. Charlie was hired as a scientist at Monsanto during the time when he was an undergraduate intern, then working full time for the company while he was still a student.
Example BioGenerator portfolio companies for Charlie include Indalo Therapeutics, Adarza BioSystems, Canopy BioSciences, Arch Oncology, Medibeacon, Confluence Discovery Technologies and Confluence Life Sciences, Arvegenix, Euclises Pharmaceuticals, SentiAR, SynerZ Medical, Plastomics, and Unleash Immuno Oncolytics.